TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes

J Mol Cell Cardiol. 2015 Apr:81:71-80. doi: 10.1016/j.yjmcc.2015.01.017. Epub 2015 Feb 2.

Abstract

TASK-1 channels have emerged as promising drug targets against atrial fibrillation, the most common arrhythmia in the elderly. While TASK-3, the closest relative of TASK-1, was previously not described in cardiac tissue, we found a very prominent expression of TASK-3 in right human auricles. Immunocytochemistry experiments of human right auricular cardiomyocytes showed that TASK-3 is primarily localized at the plasma membrane. Single-channel recordings of right human auricles in the cell-attached mode, using divalent-cation-free solutions, revealed a TASK-1-like channel with a single-channel conductance of about 30pS. While homomeric TASK-3 channels were not found, we observed an intermediate single-channel conductance of about 55pS, possibly reflecting the heteromeric channel formed by TASK-1 and TASK-3. Subsequent experiments with TASK-1/TASK-3 tandem channels or with co-expressed TASK-1 and TASK-3 channels in HEK293 cells or Xenopus oocytes, supported that the 55pS channels observed in right auricles have electrophysiological characteristics of TASK-1/TASK-3 heteromers. In addition, co-expression experiments and single-channel recordings suggest that heteromeric TASK-1/TASK-3 channels have a predominant surface expression and a reduced affinity for TASK-1 blockers. In summary, the evidence for heteromeric TASK-1/TASK-3 channel complexes together with an altered pharmacologic response to TASK-1 blockers in vitro is likely to have further impact for studies isolating ITASK-1 from cardiomyocytes and for the development of drugs specifically targeting TASK-1 in atrial fibrillation treatment.

Keywords: Atrial fibrillation; Cardiomyocytes; Heteromers; K(2P) channel; Right human auricles; TASK.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / physiology
  • Animals
  • Atrial Fibrillation / metabolism*
  • Atrial Fibrillation / pathology
  • Atrial Fibrillation / surgery
  • Benzamides / pharmacology
  • Benzeneacetamides / pharmacology
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Female
  • Gene Expression Regulation
  • HEK293 Cells
  • Heart Atria / cytology
  • Heart Atria / metabolism*
  • Humans
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*
  • Oocytes / cytology
  • Oocytes / drug effects
  • Oocytes / metabolism
  • Patch-Clamp Techniques
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels, Tandem Pore Domain / antagonists & inhibitors
  • Potassium Channels, Tandem Pore Domain / genetics
  • Potassium Channels, Tandem Pore Domain / metabolism*
  • Primary Cell Culture
  • Protein Multimerization
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Signal Transduction
  • Sulfonamides / pharmacology
  • Xenopus laevis
  • ortho-Aminobenzoates / pharmacology

Substances

  • 2-(butane-1-sulfonylamino)-N-(1-(6-methoxypyridin-3-yl)propyl)benzamide
  • A 1899
  • Benzamides
  • Benzeneacetamides
  • KCNK9 protein, human
  • Nerve Tissue Proteins
  • Potassium Channel Blockers
  • Potassium Channels, Tandem Pore Domain
  • Recombinant Proteins
  • Sulfonamides
  • ortho-Aminobenzoates
  • potassium channel subfamily K member 3